Earlybird Venture Capital — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Grey Wolf Therapeuticsgreywolftherapeutics.cominMay 2024 · $50M
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Peter Joyce(Co-founder)Tom McCarthy(Co-founder)
Co-investorsAndera PartnersCanaan PartnersOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalPfizer Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.